Establishment and clinical application of time-resolved immunofluorescence assay of lipoprotein-associated phospholipase A2

Chen, Xindong; Kewen, Zhou; Xiang, Zhongyi; Zhou, Xiumei; Wang, Yigang; Hong, Jianfeng; Huang, Biao; Qin, Yuan; Fang, Hongming

doi:10.1016/j.ab.2022.114674

Cited by 10 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, for breast cancer, while significant progress has been made in diagnosis and treatment, the prognosis remains bleak ( Zhao et al, 2017 ; Chen et al, 2022 ). It was reported that after OXA treatment, residual cancer cells revealed increased metastasis significantly.…”

Section: Discussionmentioning

confidence: 99%

Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

Chen

Zhou²,

Zhang³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Puerarin is a flavonoid molecule that widely exists in various plants. Puerarin has been reported to exhibit anti-tumor effects in various cancers. However, its exact underlying pharmacological mechanism is unclear. This study evaluated the anticancer effect of puerarin combined with oxaliplatin (OXA) in vitro and in vivo. Our results indicated that puerarin can reverse platinum-based anti-cancer drug resistance, and enhance the OXA’s anticancer effects on breast cancer. Furthermore, puerarin can inhibit migration and reverse the epithelial-mesenchymal transition (EMT) induced by low-dose OXA. Further studies showed that the carbonic anhydrase (CA) XII is a potential target of puerarin. In conclusion, puerarin is expected to become an adjuvant chemotherapy drug and potentially become one of the medicated foods for breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

Chen

Zhou²,

Zhang³

et al. 2022

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…TRFIA only uses one-step assay and it can be finished within one hour. Moreover, TRFIA shows a 20% higher measurement range than that of ELISA [48].…”

Section: Determination Of Lp-pla 2 Concentration and Activitymentioning

confidence: 91%

“…Recently, Chen et al developed a highly sensitive timeresolved fluorescence immunoassay (TRFIA) to detect serum Lp-PLA 2 concentration in breast cancer patients [48]. TRFIA assay shows better characteristics than ELISA in terms of detection time and measurement range [48]. TRFIA only uses one-step assay and it can be finished within one hour.…”

Section: Determination Of Lp-pla 2 Concentration and Activitymentioning

confidence: 99%

Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke

Zhang

Huang²,

Hu³

et al. 2022

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Ischemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in the inflammation response have been identified as diagnosing biomarkers of ischemic stroke. One of these is lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that can hydrolyze circulating oxidized phospholipids, generating proinflammatory lysophosphatidylcholine and promoting the development of atherosclerosis. In the last two decades, a number of studies have revealed that both the concentration and the activity of Lp-PLA2 are independent biomarkers of ischemic stroke. The US Food and Drug Administration (FDA) has approved two tests to determine Lp-PLA2 mass and activity for predicting stroke. In this review, we summarize the biological properties of Lp-PLA2, the detection sensitivity and limitations of Lp-PLA2 measurement, the clinical significance and association of Lp-PLA2 in ischemic stroke, and the prospects of therapeutic inhibition of Lp-PLA2 as an intervention and treatment.

show abstract

“…The labeling of anti-human IgG was performed as illustrated in Figure 1, by following the procedures described by Chen et al [28].…”

Section: Characterization Of Eu-iggmentioning

confidence: 99%

“…A solution of europium nitrate (Eu 3+ ) and p-SCN-Bn-EDTA was prepared by mixing equal volumes of equimolar solutions (3 mmol L À1 ) of Eu 3+ and p-SCN-Bn-EDTA; the solutions were prepared in PBS solution (50 mmol L À1 , pH 7.5). p-SCN-Bn-EDTA was selected because of its documented popular use for preparing europium chelates for TRFI [27,28]. Aliquot (1 mL) of europium-p-SCN-Bn-EDTA solution was mixed with an equal volume of antibody solution, and then the solution was stirred by magnetic agitation in darkness for 24 h at 4 C. The reaction solution was purified from unreacted europium-EDTA chelate by Centricon-30 filter using PBS solution and centrifugation.…”

Section: Labeling Of Anti-human Igg With Europium-edta Chelatementioning

confidence: 99%

Development of time‐resolved fluoroimmunoassay with enhanced fluorescence reaction for the quantitation of atezolizumab in plasma

Darwish,

Alzoman,

Khalil

et al. 2024

Luminescence

View full text Add to dashboard Cite

Atezolizumab (ATZ) is a human monoclonal antibody, which has been granted multiple approvals from the US Food and Drug Administration (FDA) for the immunotherapy of different types of cancer. This study describes the prototype of a time‐resolved fluoroimmunoassay (TRFIA) for the quantitation of ATZ in plasma. The assay involved the non‐competitive binding of ATZ to its specific antigen [programmed death‐ligand 1 (PD‐L1) protein]. The immune complex formed on the inner surface of the assay plate wells was quantified by anti‐human secondary antibody labeled with a chelate of europium‐ethylenediaminetetraacetic acid. The enhanced fluorescence signal was generated by an enhanced fluorescence solution composed of thenoyltrifluoroacetone, trioctylphosphine oxide, and Triton X‐100. The conditions of the TRFIA were refined, and its optimum procedures were established. The assay was validated in accordance with the immunoassay validation guidelines, and all the validation parameters were acceptable. The working range of the assay was 20–1000 pg mL−1, and its limit of quantitation was 20 pg mL−1. The assay was applied to the quantitation of ATZ in plasma samples with satisfactory accuracy and precision. The proposed TRFIA has significant benefits over the existing methodologies for the quantitation of ATZ in clinical settings.

show abstract

Establishment and clinical application of time-resolved immunofluorescence assay of lipoprotein-associated phospholipase A2

Cited by 10 publications

References 20 publications

Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

Puerarin inhibits EMT induced by oxaliplatin via targeting carbonic anhydrase XII

Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke

Development of time‐resolved fluoroimmunoassay with enhanced fluorescence reaction for the quantitation of atezolizumab in plasma

Contact Info

Product

Resources

About